BioSpace News Archive

Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the 8th CAR-TCR Summit in Boston from August 29 to September 1, 2023.

Lifecore Biomedical, Inc. announced that it received a notice on August 17, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market stating that the Company is not in compliance with Nasdaq Listing Rule 5250 because the Company failed to timely file its Annual Report on Form 10-K for the period ended May 28, 2023 with the Securities and Exchange Commission.

Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) (“Perimeter” or the “Company”) – a commercial-stage medical technology company – announced it will report its second quarter 2023 financial and operating results after the close of U.S. financial markets on Tuesday, August 29, 2023.

Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 2023 Wells Fargo Healthcare Conference on Thursday, September 7, 2023.

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), a clinical-stage biotechnology company developing novel therapies for the treatment of ophthalmic diseases

NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage

Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce that it has successfully completed its 4-week

Coherus BioSciences, Inc., announced that effective August 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 77,000 shares of the common stock of the Company to newly hired employees with a per share exercise price of $4.47, the closing trading price on August 18, 2023, the last trading date preceding the grant date.

Recor Medical, Inc. and its parent company, Otsuka Medical Devices Co., Ltd. announce the U.S. Food and Drug Administration Circulatory Systems Devices Panel of the Medical Devices Advisory Committee met to discuss the pre-market approval application for the Paradise™ Ultrasound Renal Denervation system, indicated to reduce blood pressure in patients with hypertension.

BioSig Technologies, Inc., a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, announced the release of new software features for the PURE EP™ Platform.